Global Antibody Conjugates Drugs Market 2016-2020

抗体薬物複合体(ADC)の世界市場:シアトルジェネティクス技術、ImmunoGen技術、Immunomedics技術

◆タイトル:Global Antibody Conjugates Drugs Market 2016-2020
◆商品コード:IRTNTR8911
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2016年3月31日
◆ページ数:75
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名利用)USD2,500 ⇒換算¥280,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD3,000 ⇒換算¥336,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD4,000 ⇒換算¥448,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、抗体薬物複合体(ADC)の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、抗体薬物複合体(ADC)の世界市場規模及び予測、MOA別分析、技術別分析、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況などの情報をお届けいたします。

About Antibody Drug Conjugates

ADCs, empowered monoclonal antibodies (mAbs), use chemical linkers with labile bonds to attach biologically active substances. ADCs target mAbs with the cancer killing ability of cytotoxic drugs, allowing sensitive discernment between healthy and diseased tissue.
Antibodies are the proteins produced by B-cells (from bone marrow) in the immune system. These proteins attach to antigens, which act as markers, and are then destroyed by phagocytes. B-cells produce different antibodies that attach to different sites of an antigen. mAbs, complex proteins with high molecular weight, are monospecific as they are the clones of a single parent cell. They are of three types, chimeric, humanized, and fully human, and are often used for therapeutic and diagnostic purposes.

Technavio’s analysts forecast the global ADCs market to grow at a CAGR of 41.58% during the period 2016-2020.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global ADCs market for the period 2015-2020. To calculate the market size, the report considers revenue generated from the sales of ADCs used to treat cancer.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Antibody Drug Conjugates Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• F. Hoffmann-La Roche AG
• Seattle Genetics Inc.
• Takeda Pharmaceutical Company

[Other prominent vendors]
• AbbVie
• AbGenomics
• ADC Therapeutics
• Agensys
• ALMAC Group
• Ambrx
• Astellas Pharma
• AstraZeneca
• Bayer HealthCare
• CARBOGEN AMCIS
• Celldex Therapeutics
• Daiichi Sankyo
• Endo Pharmaceuticals
• Esperance Pharmaceuticals
• Formation Biologics
• Genmab
• GlaxoSmithKline
• Immunogen
• Kairos Therapeutics
• MedImmune
• Mersana Therapeutics
• Novartis
• Oxford Biotherapeutics
• Pfizer
• Stemcentrx
• Synthon Biopharmaceuticals
• Zymeworks

[Market driver]
• Robust late-stage pipeline
• For a full, detailed list, view our report

[Market challenge]
• High developmental costs
• For a full, detailed list, view our report

[Market trend]
• Strategic alliances
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings
• Assumptions

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Overview of ADCs
• Antibodies
• Evolution of mAb therapeutics
• Conjugated mAbs
• History
• Key components in ADCs
• Next-generation ADCs
• Advantages
• Challenges
• Outsourcing of ADCs manufacturing
• Emergence of ADCs
• Current marketed ADCs

PART 06: Pipeline portfolio
• Information on pipeline candidates

PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 08: Market segmentation by MOA
• IgG1 antibodies
• HER2 antibodies

PART 09: Market segmentation by technologies used in ADCs
• Seattle Genetics (SGEN) technology
• ImmunoGen (IMGN) technology
• Immunomedics (IMMU) technology

PART 10: Geographical segmentation

PART 11: Market drivers
• Robust late-stage pipeline
• Rising prevalence of cancers
• Increase in demand for antibody conjugates
• Reimbursement policies

PART 12: Impact of drivers

PART 13: Market challenges
• High developmental costs
• Stringent regulations
• Risk of side effects

PART 14: Impact of drivers and challenges

PART 15: Market trends
• Strategic alliances
• Increased outsourcing of drug development
• Emergence of targeted and combination therapies

PART 16: Vendor landscape
• Competitive scenario
• Key news
• F. Hoffmann-La Roche
• Seattle Genetics
• Takeda Pharmaceuticals

PART 17: Appendix
• List of abbreviations

PART 18: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: Comparison of small molecule and mAbs
Exhibit 03: Preparation of mAbs
Exhibit 04: Timeline of ADCs
Exhibit 05: Key components
Exhibit 06: Components of next-generation ADCs
Exhibit 07: Advantages of ADCs
Exhibit 08: Emergence of ADCs
Exhibit 09: Marked ADCs products
Exhibit 10: Pipeline portfolio of ADCs
Exhibit 11: Pipeline share of ADCs
Exhibit 12: Market share of ADCs in clinical development
Exhibit 13: Few target antigens for ADCs in clinical development
Exhibit 14: Top five companies share in ADC pipeline
Exhibit 15: Global ADCs market 2015-2020 ($ billions)
Exhibit 16: Five forces analysis
Exhibit 17: Global ADCs market segmentation by MOA
Exhibit 18: Components in IMGN technology
Exhibit 19: Share of ADCs technologies
Exhibit 20: Global ADCs market by geography 2015
Exhibit 21: ADCs market in Americas 2015
Exhibit 22: ADCs market in Europe 2015
Exhibit 23: ADCs market in Japan 2015
Exhibit 24: Global incidence of cancer 2015 and 2020
Exhibit 25: Impact of drivers
Exhibit 26: Impact of drivers and challenges
Exhibit 27: F. Hoffmann-La Roche: Pharmaceutical division segmentation by revenue 2015
Exhibit 28: F. Hoffmann-La Roche: ADC segmentation by revenue 2015
Exhibit 29: F. Hoffmann-La Roche: Revenue generated from net product sales of Kadcyla 2013-2015 ($ millions)
Exhibit 30: F. Hoffmann-La Roche: Geographical segmentation of Kadcyla by revenue 2015
Exhibit 31: F. Hoffmann-La Roche: YoY revenue and growth rate of Kadcyla in US 2013-2015 ($ millions)
Exhibit 32: F. Hoffmann-La Roche: YoY revenue and growth rate of Kadcyla in Europe 2014 and 2015 ($ millions)
Exhibit 33: F. Hoffmann-La Roche: YoY revenue and growth rate of Kadcyla in Japan 2014-2015 ($ millions)
Exhibit 34: F. Hoffmann-La Roche: YoY revenue and growth rate of Kadcyla in ROW 2013-2015 ($ millions)
Exhibit 35: F. Hoffmann La-Roche: Kadcyla pipeline products
Exhibit 36: F. Hoffmann La-Roche: Key takeaways
Exhibit 37: Seattle Genetics: YoY revenue and growth rate of ADCETRIS in US and Canada ($ millions)
Exhibit 38: Seattle Genetics: ADCETRIS developmental pipeline
Exhibit 39: Seattle Genetics: ADCs pipeline and seven clinical trial programs
Exhibit 40: Seattle Genetics: ADC collaborations
Exhibit 41: Seattle Genetics: Key takeaways
Exhibit 42: Takeda: Business segmentation by revenue 2015
Exhibit 43: Takeda Pharmaceuticals: Geographical segmentation by revenue 2015
Exhibit 44: Takeda Pharmaceuticals: YoY growth and revenue generated from ADCETRIS (except US and Canada) 2013-2015 ($ millions)
Exhibit 45: Takeda Pharmaceuticals: Key takeaways



【掲載企業】

F. Hoffmann-La Roche AG, Seattle Genetics Inc., Takeda Pharmaceutical Company, AbbVie, AbGenomics, ADC Therapeutics, Agensys, ALMAC Group, Ambrx, Astellas Pharma, AstraZeneca, Bayer HealthCare, CARBOGEN AMCIS, Celldex Therapeutics, Daiichi Sankyo, Endo Pharmaceuticals, Esperance Pharmaceuticals, Formation Biologics, Genmab, GlaxoSmithKline, Immunogen, Kairos Therapeutics, MedImmune, Mersana Therapeutics, Novartis, Oxford Biotherapeutics, Pfizer, Stemcentrx, Synthon Biopharmaceuticals, Zymeworks.

【資料のキーワード】

抗体薬物複合体(ADC)、シアトルジェネティクス技術、ImmunoGen技術、Immunomedics技術、モノクローナル抗体、薬剤、パイプライン

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[抗体薬物複合体(ADC)の世界市場:シアトルジェネティクス技術、ImmunoGen技術、Immunomedics技術] (Global Antibody Conjugates Drugs Market 2016-2020 / IRTNTR8911)販売に関する免責事項
[抗体薬物複合体(ADC)の世界市場:シアトルジェネティクス技術、ImmunoGen技術、Immunomedics技術] (Global Antibody Conjugates Drugs Market 2016-2020 / IRTNTR8911)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆